series-a
Stage
2011
Founded
1
Investors
About
RUTI Immune is a clinical-stage biopharmaceutical company developing a therapeutic vaccine, RUTI®, for the treatment of latent and active tuberculosis. The company aims to shorten treatment duration and prevent recurrence of the disease.
Explore RUTI Immune's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.